Recommendations for antiretroviral therapy during pregnancy: prevention for the child; treatment for the mother.
(1) Treatment with zidovudine has led to a fall in the mother-to-child HIV transmission during pregnancy and the first few weeks of neonatal life.  (2) Ongoing trials are assessing the preventive efficacy of two-drug and three-drug antiretroviral regimens in this setting.  (3) Pending the results of these studies, treatment with zidovudine is recommended for all HIV-infected pregnant women.  (4) Current therapeutic strategies may lead to the prescription or continuation of multidrug antiretroviral regimens for seropositive pregnant women.  (5) Available information on the possible adverse effects of antiretroviral drugs on the pregnant woman, fetus and child are limited.  (6) Two reports propose similar guidelines for the management of seropositive pregnant women and their children during the first weeks of life.
D019380:Anti-HIV Agents / Q000627:therapeutic use* / Q000633:toxicity; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D005602:France; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control / Q000635:transmission; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000517:prevention & control; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy; D014481:United States; D015215:Zidovudine / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D015215:Zidovudine